In addition, PYY may also improve islet secretory function post-MBS [48], and GLP-1 is known to increase glucose-dependent insulin secretion and suppress glucagon during hyperglycemia [49], all factors that likely contribute to the metabolic improvements seen in participants of IMPROVE-T2D. Here, GLP1R is linked to Hyperglycemia.